Your browser is no longer supported. Please, upgrade your browser.
AZRX AzurRx BioPharma, Inc. daily Stock Chart
AzurRx BioPharma, Inc.
Index- P/E- EPS (ttm)-1.00 Insider Own4.70% Shs Outstand16.98M Perf Week-0.44%
Market Cap38.37M Forward P/E- EPS next Y-0.62 Insider Trans0.00% Shs Float10.87M Perf Month-7.76%
Income-12.60M PEG- EPS next Q-0.20 Inst Own18.80% Short Float0.59% Perf Quarter-7.76%
Sales- P/S- EPS this Y53.50% Inst Trans0.69% Short Ratio0.69 Perf Half Y-12.06%
Book/sh0.50 P/B4.52 EPS next Y- ROA-171.40% Target Price7.00 Perf Year-24.16%
Cash/sh0.44 P/C5.19 EPS next 5Y- ROE-381.00% 52W Range2.10 - 4.08 Perf YTD-37.87%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-44.61% Beta-
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low7.62% ATR0.20
Employees12 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)43.70 Volatility10.68% 8.27%
OptionableNo Debt/Eq0.04 EPS Q/Q18.50% Profit Margin- Rel Volume0.25 Prev Close2.45
ShortableYes LT Debt/Eq0.00 EarningsNov 12 Payout- Avg Volume92.70K Price2.26
Recom1.50 SMA20-7.98% SMA50-11.28% SMA200-18.30% Volume23,298 Change-7.76%
Oct-17-18Initiated Oppenheimer Outperform $6
Jul-24-17Initiated H.C. Wainwright Buy $8
Nov-01-18 07:30AM  AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI GlobeNewswire +8.60%
Oct-16-18 07:30AM  AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis GlobeNewswire
Sep-24-18 03:45PM  AZRX: Final Results from Phase II EPI Trial Zacks Small Cap Research +11.32%
07:45AM  AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis GlobeNewswire
Aug-28-18 09:45AM  AZRX: Phase 2 Cystic Fibrosis Study to Start Zacks Small Cap Research
08:30AM  AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th GlobeNewswire
Aug-01-18 08:30AM  AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th) GlobeNewswire -6.27%
Jul-02-18 09:30AM  AZRX: AzurRx Announces Completion of Phase 2a MS1819 Trial Zacks Small Cap Research
Jun-29-18 08:30AM  AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency GlobeNewswire +5.59%
May-30-18 08:03AM  AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer GlobeNewswire
May-02-18 11:15AM  AZRX: AzurRx Raises Capital After Confirming Results Zacks Small Cap Research +8.05%
May-01-18 09:10AM  AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock GlobeNewswire -7.74%
07:51AM  Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings Benzinga
Apr-30-18 04:15PM  AzurRx BioPharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-23-18 08:45AM  AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI) GlobeNewswire -11.92%
Apr-18-18 07:45AM  AzurRx BioPharma Announces Positive Preclinical Data with AZX1103 GlobeNewswire
Apr-13-18 01:15PM  AZRX: French Sites to Help Achieve 1H:18 Enrollment Goal Zacks Small Cap Research +10.86%
Mar-02-18 09:00AM  Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC ACCESSWIRE
Feb-28-18 08:30AM  AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th) GlobeNewswire -5.80%
Feb-12-18 08:15AM  AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD GlobeNewswire
Feb-08-18 04:30PM  AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th) GlobeNewswire
Jan-30-18 09:00AM  SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00 ACCESSWIRE +13.73%
Jan-18-18 08:00AM  AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency GlobeNewswire
Jan-16-18 11:16PM  AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants GlobeNewswire
Dec-20-17 07:30AM  AzurRx BioPharma Announces Publication of U.S. Patent Application for AZX1101 GlobeNewswire
Dec-04-17 07:00AM  AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th) GlobeNewswire
Dec-01-17 05:50PM  Why AzurRx BioPharma Incs (AZRX) Investor Composition Impacts Your Returns Simply Wall St.
07:30AM  AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th) GlobeNewswire
Oct-20-17 08:30AM  AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission GlobeNewswire
Oct-16-17 08:30AM  AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors GlobeNewswire -5.88%
Oct-11-17 03:54PM  Healthcare Industry Trends And Its Impact On AzurRx BioPharma Inc (AZRX) Simply Wall St.
Sep-27-17 09:00AM  AZRX: Update on MS1819 Phase II Trial Zacks Small Cap Research
08:30AM  AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI) GlobeNewswire
Sep-25-17 08:30AM  AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer GlobeNewswire
Sep-05-17 08:30AM  MicroCap Review Magazine Fall 2017 Issue Now Available ACCESSWIRE +5.74%
Aug-28-17 01:00PM  AZRX: Fall Data Announcement for MS 1819 Zacks Small Cap Research -5.90%
Aug-24-17 08:00AM  AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12 GlobeNewswire +7.50%
Aug-23-17 08:00AM  AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis GlobeNewswire
Jun-08-17 08:00AM  AzurRx BioPharma Announces Closing of $5.0 Million Private Financing GlobeNewswire +11.60%
Jun-05-17 04:30PM  AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June 6) and the 2017 Marcum MicroCap Conference (June 15) GlobeNewswire
Apr-17-17 02:00PM  AZRX: MS 1819 Trial, First Look Positive; 2016 Results Zacks Small Cap Research +9.92%
Apr-11-17 08:00AM  AzurRx Provides Update on MS1819 Phase II Trial GlobeNewswire
Mar-08-17 09:33AM  AzurRx Announces Addition of Charles J Casamento to the Board of Directors GlobeNewswire
Mar-01-17 11:18AM  LifeSci Capital Initiates Coverage of AzurRx BioPharma Accesswire
Jan-25-17 10:00AM  AZRX: Non-systemic Focus on the GI Market Zacks Small Cap Research
Jan-05-17 03:09PM  Is AzurRx About to Transform the Gastrointestinal Treatment Industry? +9.41%
Dec-28-16 08:00AM  AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference GlobeNewswire
Dec-27-16 03:54PM  An Emerging Leader to Treat Gastrointestinal Disease
Dec-21-16 08:00AM  AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency GlobeNewswire
Dec-12-16 08:00AM  WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma GlobeNewswire
Dec-06-16 08:00AM  AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology GlobeNewswire
05:59AM  Coverage initiated on AzurRx BioPharma by WallachBeth
Dec-01-16 08:00AM  AzurRx CEO Provides Shareholders With a "State of the Union" Communication GlobeNewswire
Nov-30-16 05:17PM  AzurRx BioPharma to Present at the 9th Annual LD Micro Main Event Accesswire
Oct-16-16 09:15AM  IPO Market Could Launch 4 New Firms Next Week 24/7 Wall St.
Oct-12-16 11:42AM  Heres Why AzurRx BioPharma, Lions Gate Entertainment, Barracuda Networks and Two Other Stocks Are on the Move Today Insider Monkey
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BORKOWSKI EDWARDDirectorJan 11Option Exercise2.5013,68034,20013,680Jan 16 06:13 PM
BORKOWSKI EDWARDDirectorJan 11Option Exercise2.5022,32055,800297,946Jan 16 06:13 PM